Datascope's mixed 1995 fortunes
This article was originally published in Clinica
Executive Summary
US medical device manufacturer Datascope experienced mixed fortunes for its two main businesses in fiscal 1995 ended June. Patient monitoring sales declined 9% after Datascope was forced to recall its "point of view" monitor in April. Cardiac assist sales, meanwhile, rose 18% supported by demand for intra-aortic balloon catheters and balloon pumps. Datascope received an approvable letter from the US FDA for VasoSeal for coronary angiography and angioplasty in July (see Clinica No 664, p 18).
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.